Exocrine secretion oppression as game changing tool in acute pancreatitis surgical treatment
Author:
Podpryatov S. E.,Ivanko O. V.,Popdryatov S. S.,Levytska O. V.,Korchak V. P.
Abstract
the aim of the work: to assess changes in tactic of surgical treatment of acute destructive pancreatitis (ADP) due to octreotide prescription in high dose 1 mg/day (OHD).
Materials and Methods. OHD had been used as treatment of 6 patients with ADP. Within first two days of illness in such way were treated 4 patients (group1), in terms of two weeks after disease beginning OHD treatment had been applied to 2 patients (group2). All patients gave an informed consent to applied treatment.
There were 2 women and 4 men in the age from 17 to 75 years. Gallstone disease combined with excessive eating lied ground to ADP outbreak in 2 patients, alcohol excessive consumption combined with overeating in 4.
In our observations acute pancreatitis was diagnosed on integrated assessing results of clinical appearances, and results of laboratory and instrumental examining. OHD had been prescribed to every patient immediately after the diagnosis had been stated.
Results and Discussion. All patients from group 1 became free from clinical signs of ADP two hours after OHD administering. Prolongation of the OHD use during next two days resulted in normalizing of general clinical state and amylase level. In one patient after two days of OHD treatment clinical signs didn’t normalized. There left some abdominal pain and substantial meteorism.
Both patients from group 2 obtain stabilization of general clinical status with the clear expression a sign of a local abscess. By means of computed and magnetic tomography almost two local niduses in every patient had been localized and subsequently subjected it to healing through a mini-invasion approach. Both patients recovered.
Conclusion. Thus, we can suggest that proposed method of OHD treatment cause stabilization of pancreatic parenchyma what may be the reason for observed immediate break of inflammation.
Publisher
Ternopil State Medical University
Reference14 articles.
1. Colvin, S.D., Smith, E.N., Morgan, D.E., & Porter, K.K. (2020). Acute pancreatitis: an update on the revised Atlanta classification. Abdom. Radiol. (NY), 45 (5): 1222-1231. DOI: 10.1007/s00261-019-02214-w. 2. Bhatti, K.M., Rehman, S., Ahmed, S.E., & Canelo, R. (2022). Management of complicated acute pancreatitis: the role of hub-and-spoke model. J. Coll. Physicians Surg. Pak., 32 (5): 575-580. DOI: 0.29271/jcpsp.2022.05.575. 3. Karakoyunlar, O., Sivrel, E., Tanir, N., & Deneçli, A. G. (1999). High dose octreotide in the management of acute pancreatitis. Hepatogastroenterology, 46(27), 1968-1972. 4. Nikou, G.C., Arnaoutis, T.P., Giamarellos-Bourboulis, E.J., Samolada, O., Vafiadis-Zouboulis, I., Katsilambros, N., & Arvanitakis, C. (2001). The significance of the dosage adjustment of octreotide in the treatment of acute pancreatitis of moderate severity. Hepatogastroenterology, 48 (42), 1754-1757. 5. Meng, L., Wu, Z., & Zhang, H. (2019). Effect of ulinastatin combined with octreotide on serum endothelin, endotoxin levels and immune function in acute pancreatitis. J. Coll. Physicians Surg. Pak., 29 (1): 90-92. DOI: 10.29271/jcpsp.2019.01.90.
|
|